收费全文 | 293803篇 |
免费 | 17222篇 |
国内免费 | 392篇 |
耳鼻咽喉 | 4210篇 |
儿科学 | 10244篇 |
妇产科学 | 10164篇 |
基础医学 | 44642篇 |
口腔科学 | 7486篇 |
临床医学 | 23792篇 |
内科学 | 55060篇 |
皮肤病学 | 6297篇 |
神经病学 | 20871篇 |
特种医学 | 11593篇 |
外国民族医学 | 43篇 |
外科学 | 46492篇 |
综合类 | 7715篇 |
一般理论 | 160篇 |
预防医学 | 19689篇 |
眼科学 | 6930篇 |
药学 | 20790篇 |
中国医学 | 738篇 |
肿瘤学 | 14501篇 |
2018年 | 3546篇 |
2017年 | 2624篇 |
2016年 | 3040篇 |
2015年 | 3450篇 |
2014年 | 4550篇 |
2013年 | 7179篇 |
2012年 | 9050篇 |
2011年 | 9434篇 |
2010年 | 6116篇 |
2009年 | 5529篇 |
2008年 | 8649篇 |
2007年 | 9506篇 |
2006年 | 9341篇 |
2005年 | 8940篇 |
2004年 | 8655篇 |
2003年 | 8145篇 |
2002年 | 7743篇 |
2001年 | 13314篇 |
2000年 | 13626篇 |
1999年 | 11338篇 |
1998年 | 2883篇 |
1997年 | 2615篇 |
1996年 | 2478篇 |
1995年 | 2534篇 |
1994年 | 2336篇 |
1992年 | 8307篇 |
1991年 | 8450篇 |
1990年 | 8257篇 |
1989年 | 8073篇 |
1988年 | 7308篇 |
1987年 | 7068篇 |
1986年 | 6717篇 |
1985年 | 6513篇 |
1984年 | 4751篇 |
1983年 | 4110篇 |
1982年 | 2458篇 |
1979年 | 4415篇 |
1978年 | 3216篇 |
1977年 | 2722篇 |
1976年 | 2484篇 |
1975年 | 2822篇 |
1974年 | 3348篇 |
1973年 | 3355篇 |
1972年 | 3112篇 |
1971年 | 2946篇 |
1970年 | 2832篇 |
1969年 | 2580篇 |
1968年 | 2535篇 |
1967年 | 2370篇 |
1966年 | 2259篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献Background
During coronavirus disease 2019 (COVID-19)–related operating room closures, some multidisciplinary thoracic oncology teams adopted a paradigm of stereotactic ablative radiotherapy (SABR) as a bridge to surgery, an approach called SABR-BRIDGE. This study presents the preliminary surgical and pathological results.Methods
Eligible participants from four institutions (three in Canada and one in the United States) had early-stage presumed or biopsy-proven lung malignancy that would normally be surgically resected. SABR was delivered using standard institutional guidelines, with surgery >3 months following SABR with standardized pathologic assessment. Pathological complete response (pCR) was defined as absence of viable cancer. Major pathologic response (MPR) was defined as ≤10% viable tissue.Results
Seventy-two patients underwent SABR. Most common SABR regimens were 34 Gy/1 (29%, n = 21), 48 Gy/3–4 (26%, n = 19), and 50/55 Gy/5 (22%, n = 16). SABR was well-tolerated, with one grade 5 toxicity (death 10 days after SABR with COVID-19) and five grade 2–3 toxicities. Following SABR, 26 patients underwent resection thus far (13 pending surgery). Median time-to-surgery was 4.5 months post-SABR (range, 2–17.5 months). Surgery was reported as being more difficult because of SABR in 38% (n = 10) of cases. Thirteen patients (50%) had pCR and 19 (73%) had MPR. Rates of pCR trended higher in patients operated on at earlier time points (75% if within 3 months, 50% if 3–6 months, and 33% if ≥6 months; p = .069). In the exploratory best-case scenario analysis, pCR rate does not exceed 82%.Conclusions
The SABR-BRIDGE approach allowed for delivery of treatment during a period of operating room closure and was well-tolerated. Even in the best-case scenario, pCR rate does not exceed 82%. 相似文献We investigated the relationships between physical isolation at home during the period when many US states had shelter-in-place orders and subsequent longitudinal trajectories of depression, anxiety, and loneliness in older adults over a 6 month follow-up.
MethodsData were from monthly online questionnaires with US adults aged ≥ 55 in the nation-wide COVID-19 Coping Study (April through October 2020, N = 3978). Physical isolation was defined as not leaving home except for essential purposes (0, 1–3, 4–6, and 7 days in the past week), measured at baseline (April–May). Outcomes were depressive symptoms (8-item Center for Epidemiological Studies Depression Scale), anxiety symptoms (5-item Beck Anxiety Inventory), and loneliness (3-item UCLA loneliness scale), measured monthly (April–October). Multivariable, population- and attrition-weighted linear mixed-effects models assessed the relationships between baseline physical isolation with mental health symptoms at baseline and over time.
ResultsPhysical isolation (7 days versus 0 days in the past week) was associated with elevated depressive symptoms (adjusted β = 0.85; 95% CI 0.10–1.60), anxiety symptoms (adjusted β = 1.22; 95% CI 0.45–1.98), and loneliness (adjusted β = 1.06; 95% CI 0.51–1.61) at baseline, but not with meaningful rate of change in these mental health outcomes over time. The symptom burden of each mental health outcome increased with increasing past-week frequency of physical isolation.
ConclusionDuring the early COVID-19 pandemic, physical isolation was associated with elevated depressive symptoms, anxiety symptoms, and loneliness, which persisted over time. These findings highlight the unique and persistent mental health risks of physical isolation at home under pandemic control measures.
相似文献